<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"><url><loc>https://pvigi.com/</loc><lastmod>2026-11-20</lastmod><priority>1.0</priority></url><url><loc>https://pvigi.com/services/</loc><lastmod>2026-11-20</lastmod><priority>0.9</priority></url><url><loc>https://pvigi.com/services/pharmacovigilance/</loc><lastmod>2026-11-20</lastmod><priority>0.9</priority></url><url><loc>https://pvigi.com/services/qppv-local-pv-representation/</loc><lastmod>2026-11-20</lastmod><priority>0.9</priority></url><url><loc>https://pvigi.com/services/literature-monitoring/</loc><lastmod>2026-11-20</lastmod><priority>0.9</priority></url><url><loc>https://pvigi.com/services/regulatory-affairs-marketing-authorisation/</loc><lastmod>2026-11-20</lastmod><priority>0.9</priority></url><url><loc>https://pvigi.com/services/regulatory-intelligence/</loc><lastmod>2026-11-20</lastmod><priority>0.9</priority></url><url><loc>https://pvigi.com/services/ai-driven-pharmacovigilance/</loc><lastmod>2026-11-20</lastmod><priority>0.9</priority></url><url><loc>https://pvigi.com/services/clinical-trial-safety-cro/</loc><lastmod>2026-11-20</lastmod><priority>0.9</priority></url><url><loc>https://pvigi.com/services/pv-consulting-audits/</loc><lastmod>2026-11-20</lastmod><priority>0.9</priority></url><url><loc>https://pvigi.com/case-studies/</loc><lastmod>2026-11-20</lastmod><priority>0.7</priority></url><url><loc>https://pvigi.com/case-studies/local-literature-review-signal-detection/</loc><lastmod>2026-11-20</lastmod><priority>0.6</priority></url><url><loc>https://pvigi.com/case-studies/regulatory-intelligence-28-countries/</loc><lastmod>2026-11-20</lastmod><priority>0.6</priority></url><url><loc>https://pvigi.com/case-studies/risk-management-plan-marketed-product/</loc><lastmod>2026-11-20</lastmod><priority>0.6</priority></url><url><loc>https://pvigi.com/case-studies/qppv-lcppv-25-countries/</loc><lastmod>2026-11-20</lastmod><priority>0.6</priority></url><url><loc>https://pvigi.com/case-studies/benefit-risk-assessment-high-risk-product/</loc><lastmod>2026-11-20</lastmod><priority>0.6</priority></url><url><loc>https://pvigi.com/case-studies/adverse-event-case-processing-database/</loc><lastmod>2026-11-20</lastmod><priority>0.6</priority></url><url><loc>https://pvigi.com/case-studies/susar-dsur-submissions-cro/</loc><lastmod>2026-11-20</lastmod><priority>0.6</priority></url><url><loc>https://pvigi.com/case-studies/pharmacovigilance-audit-no-critical-findings/</loc><lastmod>2026-11-20</lastmod><priority>0.6</priority></url><url><loc>https://pvigi.com/case-studies/regulatory-market-entry-mena-europe/</loc><lastmod>2026-11-20</lastmod><priority>0.6</priority></url><url><loc>https://pvigi.com/resources/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/regulation-on-the-safety-of-medicinal-products/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/ilaclarin-guvenliligi-hakkinda-yonetmelik/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/guideline-on-good-pharmacovigilance-practicesgpvp-module-i-management-and-reporting-of-adverse-drugreactions/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/iyi-farmakovijilans-uygulamalari-ifu-kilavuzu-modul-i-advers-ilac-reaksiyonlarinin-yonetimi-ve-bildirimi/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/guideline-on-good-pharmacovigilance-practices-gpvp-module-ii-additional-monitoring/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/module_v/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/guideline-on-good-pharmacovigilance-practices/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/iyi-farmakovijilans-uygulamalari-kilavuzu-ek-i-tanimlar/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/ifu-kilavuzu-modul-ii-ek-izlem/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/ifu-kilavuzu-modul-iii-periyodik-yarar-risk-degerlendirme-raporu/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/ifu-kilavuzu-modul-iv-farmakovijilans-kalite-sistemi/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/turkish-gvp-module-iv-pharmacovigilance-quality-system/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/ifu-kilavuzu-modul-v-farmakovijilans-sistem-ana-dosyasi/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/turkish-gvp-module-v-pharmacovigilance-system-master-file/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/ifu-kilavuzu-modul-vi-risk-yonetimi-sistemleri/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/turkish-gvp-module-vi-risk-management-systems/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/ifu-kilavuzu-modul-vi-ek-1-covid-19-asilari-risk-yonetim-planlari/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/turkish-gvp-module-vi-annex-1-covid-19-vaccine-rmps/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/ifu-kilavuzu-modul-vii-sinyal-yonetimi/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/turkish-gvp-module-vii-signal-management/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/ifu-kilavuzu-modul-viii-guvenlilik-iletisimi/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/turkish-gvp-module-viii-safety-communication/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/ifu-kilavuzu-modul-ix-risk-minimizasyon-tedbirleri/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/ifu-kilavuzu-modul-ix-ek-1-egitim-materyalleri/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/turkish-gvp-module-ix-annex-1-educational-materials/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/ifu-kilavuzu-modul-x-pazarlama-oncesi-yarar-risk-degerlendirmesi/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/ifu-kilavuzu-modul-xi-pazarlama-sonrasi-yarar-risk-degerlendirmesi/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/turkish-gvp-module-xi-post-marketing-benefit-risk-assessment/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/farmakovijilans-faaliyetlerinde-kisisel-verilerin-korunmasi-kilavuzu/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/personal-data-protection-in-pharmacovigilance-turkey/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/farmakovijilans-faaliyetlerinde-kriz-yonetimi-rehberi/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/farmakovijilans-indikatorleri-rehberi/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/farmakovijilans-faaliyetlerinde-guven-uygulamalari-rehberi/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/reliance-in-pharmacovigilance-guideline-turkey/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/titck-farmakovijilans-sistemi-kilavuzu/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/titck-pharmacovigilance-system-guideline/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/sozlesmeli-farmakovijilans-hizmet-kuruluslari-kilavuzu/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/ich-e2b-r3-bogr-elektronik-iletimi-soru-cevap/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/ich-e2b-r3-bogr-elektronik-iletimi-uygulama-kilavuzu/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/countries/</loc><lastmod>2026-11-20</lastmod><priority>0.9</priority></url><url><loc>https://pvigi.com/about/</loc><lastmod>2026-11-20</lastmod><priority>0.7</priority></url><url><loc>https://pvigi.com/contact/</loc><lastmod>2026-11-20</lastmod><priority>0.8</priority></url><url><loc>https://pvigi.com/privacy/</loc><lastmod>2026-11-20</lastmod><priority>0.3</priority></url><url><loc>https://pvigi.com/kvkk/</loc><lastmod>2026-11-20</lastmod><priority>0.2</priority></url></urlset>
